AbbVie Sees FY Adj EPS $13.95-Adj EPS $13.99 >ABBV

What happened

AbbVie issued full-year adjusted earnings per share guidance of $13.95 to $13.99. Adjusted earnings per share is a profit measure that excludes certain items. The company is identified by its ABBV ticker symbol in the headline.

Confirmed

Global impact / market context

Earnings guidance tells investors how much profit per share AbbVie expects for the year, helping them judge whether the stock looks cheap or expensive. The four-cent range suggests management sees limited uncertainty in its ABBV forecast.

Analyst inference

The article provides only AbbVie's guidance figure and no prior forecast or reported result for comparison, so investors cannot tell whether $13.95 to $13.99 is above, below, or in line with earlier ABBV expectations.

Analyst inference

What to watch

1. Watch for AbbVie's eventual full-year adjusted earnings per share result to see whether it lands within the $13.95 to $13.99 range the company guided to. Confirmed
2. Compare this ABBV guidance with any earlier AbbVie forecast or analyst estimate to judge whether the outlook improved or weakened, since the article provides no baseline. Proposed
3. Track AbbVie's quarterly reports for changes to selling costs, research spending, or drug revenue that could push profit per share toward the low or high end of the range. Analyst inference

Evidence

• Original source link unavailable